Promising use of metformin in treating neurological disorders: biomarker-guided therapies

Abstract

Neurological disorders are a diverse group of conditions that affect the nervous system and include neurodegenerative diseases (Alzheimer’s disease, multiple sclerosis, Parkinson’s disease, Huntington’s disease), cerebrovascular conditions (stroke), and neurodevelopmental disorders (autism spectrum disorder). Although they affect millions of individuals around the world, only a limited number of effective treatment options are available today. Since most neurological disorders express mitochondria-related metabolic perturbations, metformin, a biguanide type II antidiabetic drug, has attracted a lot of attention to be repurposed to treat neurological disorders by correcting their perturbed energy metabolism. However, controversial research emerges regarding the beneficial/detrimental effects of metformin on these neurological disorders. Given that most neurological disorders have complex etiology in their pathophysiology and are influenced by various risk factors such as aging, lifestyle, genetics, and environment, it is important to identify perturbed molecular functions that can be targeted by metformin in these neurological disorders. These molecules can then be used as biomarkers to stratify subpopulations of patients who show distinct molecular/pathological properties and can respond to metformin treatment, ultimately developing targeted therapy. In this review, we will discuss mitochondria-related metabolic perturbations and impaired molecular pathways in these neurological disorders and how these can be used as biomarkers to guide metformin-responsive treatment for the targeted therapy to treat neurological disorders.

Neuro-Adipokine Crosstalk in Alzheimer’s Disease

“…These drugs that were originally designed to target neurological disorders can be adapted to target metabolic disorders. Trending metabolic drugs utilized for obesity and type 2 diabetes mellitus, such as glucagon-like-peptide-1 receptor agonist and metformin, are being repurposed as novel treatment strategies for neurodegenerative diseases [ 109 , 110 ]. These treatments have a direct effect on the brain, as well as an indirect effect by improving overall metabolic health including adipokine profiles.…”